What they're saying"Applikate has an excellent team with a breakthrough technology that has the potential to change the world of histopathology."
What they're saying"Applikate’s new technologies will positively disrupt an entire branch of medical science and business."
What they're saying"Applikate has developed a unique approach to pathology that accelerates diagnosis, eliminates costs, and negates the need for wax embedding and toxic agents. I believe the company will disrupt the field of histology."
Many Hands Make "Light" Work
Applikate was founded by pioneers in transforming histology
As leaders in pathology, biomedical engineering, optics, and applied physics, Applikate’s founders designed, built, tested, and are now delivering a patented histology platform that is as elegant as it is revolutionary.
We follow best practices in business management, which includes extensive planning, operational execution, and clear accountability.
Applikate Technologies is a hardware and software company that has developed the first automated histology platform with integrated digital imaging. Our patented technology stains and images whole samples without the need for physical slicing. The platform automates the pathology workflow, cuts processing time, lowers labor and materials costs, improves image quality, and reduces the risk of misdiagnosis.
Since 2013, Applikate has been revolutionizing pathology, reducing medical errors, and lowering cost.
Torres and Levene establish Applikate Technologies, LLC in New Haven, CT after publishing an innovative approach to clinical histology using unique chemical combinations and advanced microscopy.
National Cancer Institute awards Applikate’s first NIH SBIR grant.
Initial version of Applikate’s Stackstreamer software demonstrates practical, web-based, image navigation of arbitrarily large three-dimensional digital histology data sets.
Proprietary Tissue Processing
Applikate develops proprietary tissue processing method for multiphoton imaging with cost, speed, and quality features enabling clinical use.
Applikate receives NIH SBIR award from National Institute of Biomedical Imaging and Bioengineering.
Published article illustrates unique capabilities of CHiMP for assessment of human renal tissue specimens.
First Proprietary System
Applikate builds first advanced proprietary system for high-speed, high-resolution, multiphoton microscopy of clinical specimens.
Applikate receives follow-on NIH/NCI SBIR grant funding to continue CHiMP development.
Applikate builds first prototype of automated tissue processor for CHiMP that requires no human handling.
First Clinical Study
Applikate Technologies and Yale-New Haven Hospital begin first clinical study using Applikate’s CHiMP platform for prostate cancer patients.
Fourth NIH Award
Applikate awarded fourth NIH/NCI SBIR to explore specialized applications of CHiMP.
Applikate In The Media
Various publications and presentations highlight CHiMP’s potential impact in breast cancer, liver disease, kidney disease, and research histology applications.
Applikate receives grant from National Institute of Diabetes and Digestive and Kidney Diseases for development focused on renal pathology.
Key Patents Granted
U.S. Patent Office grants key patents to Applikate covering various aspects of the CHiMP platform.
Applikate Joins CDL
Applikate joins the Creative Destruction Lab (CDL) business incubator.
Prostate Cancer Diagnosis Study
Published prostate cancer diagnostics study demonstrates viability of CHiMP as a primary diagnostic platform with critical advantages.
CDL showcases Applikate at its annual Super Session.
Over-Subscribed Seed Round
Applikate closes over-subscribed seed round and becomes Applikate Technologies, Inc.
Second Clinical Validation Round
Applikate begins second phase of clinical validation studies using CHiMP.